← Oncology Approval Tracker

FDA DECISION ·

Tecentriq + Avastin

atezolizumab + bevacizumab · Genentech

FDA approvalNew or expanded indicationHepatocellular carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with unresectable or metastatic hepatocellular carcinoma who had not received systemic therapy.

LAMPGEN ANALYSIS

Why it matters

Established an immunotherapy and antiangiogenic combination as a first-line option.

What research teams should watch

Plan assessment of bleeding risk and varices and capture baseline liver function.

PRIMARY RECORDS

Sources